VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd

Bullboard Posts

Comment by snuff69on Feb 21, 2018 11:11am

211 Views

Post# 27594118

RE:RE:Everybody Is ANXIOUSLY Waiting For The Killer News !!!

Here’s the letter that was attached to this mornings press release , sounds very promising

Dear Stakeholder;

Attached is a new release announcing our first installation of a VMS+ system at “The Maz" in Edmonton. Here is some background information.

1. The Maz had an original VMS for RV only and now has upgraded to the VMS+ for all 4 chambers of the heart.
2. As usual, they want to try it out on a select group of patients until they adopt it for everyone. Accordingly, they are going to study “technically-difficult” patients first and then cancer patients.
3. "Technically-difficult” is jargon for patients (30-40% of people), who give poor quality images, but as you know the VMS+ excels at analyzing studies where only a small area in each of the 16 normal views can be discerned. It is by aggregating all these little bits of information and using an AI approach we can get the correct result.
4. We have been encourage by our expert users, who have been surprised to be able to analyze what they would have previously said were “unreadable” echocardiograms.
5. Normally, such patients would have gone on to have contrast media injected and have the study redone. This is dangerous (allergic reaction to contrast media), expensive, traumatic and time-consuming, as it requires an IV nurse to be summoned and waited for and numerous people, especially children do not like needles.
6. We continue our quest to improve cardiac diagnosis for all, especially for children. While we originally wanted to avoid MRI, we now see the potential to eliminate needles and contrast media.
7. The study will not take long as the Maz is a busy cardiac centre and so we should have something to report Soon
8. As usual, call me or send me message of you have questions.

Thanks for your continued support and interest in VPT.

Regards,

George Adams, PhD, ICD.D
CEO
Ventripoint Diagnostics Ltd..
Cell: 519-803-6937
TSXV: VPT
www.ventripoint.com
The world's first •dot imaging• company

George Adams

bampa3262@gmail.com